AKBLF

ALK-Abelló A/S

AKBLF, USA

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mites, grass and tree pollen, ragweed, Japanese cedar, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that provide support, guidance, and relief, as well as smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. It has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX, a grass pollen allergy tablet; CEDARCURE, a tablet for the treatment of Japanese cedar pollen induced allergy; and MITICURE for the treatment of house dust mite-induced allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

https://www.alk.net

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
AKBLF
stock
AKBLF

ALK-Abelló A/S (OTC:AKBLF) Trading Up 1.8% – What’s Next? Defense World

Read more →
AKBLF
stock
AKBLF

ARS Pharmaceuticals: 'Betting On The Come' (NASDAQ:SPRY) Seeking Alpha

Read more →

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

46.28

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

1.31

Low 1

High 3

Return on Equity (ROE)

-

Very Low

5.09 %

Low 5%

High 25%

Return on Assets (ROA)

-

Low

3.71 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

19.67 %

Low 5%

High 15%

Debt to Equity

-

Very High

0.37

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of ALK-Abelló A/S

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

0.2219

EPS Estimate

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.8)
GARP
Fair GARP(5)
Growth
Moderate Growth(4)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(8)
Value
Undervalued(6.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.